
Health & Fitness
Growing stronger, day by day
How to stay positive by developing a 'growth mindset'
READ MORETekes, the Finnish Funding Agency for Innovation, has granted a €2,903,000 loan to Herantis Pharma Plc to support its clinical study of CDNF for the treatment of Parkinson’s disease. The loan was granted conditionally, subject to obtaining regulatory approval for the clinical study.
Pekka Simula, CEO of Herantis Pharma, added: “We are very excited about our opportunity to translate the results of years of leading academic research to clinical stage, hopefully for the benefit of as many patients as possible.”
Herantis aims to start its clinical development programme with regulatory submissions in Finland and Sweden by the end of 2015. Patient treatments are expected to begin in the first half of 2016. The company expects to recruit 18 patients with Parkinson’s disease in this first-in-human study of CDNF.
How to stay positive by developing a 'growth mindset'
READ MOREEuropean coalition set to roll out new and simple composite scale
READ MOREA UK farm is giving a new sense of belonging to men with Parkinson’s
READ MORE
Comments